Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GLPG1205 in Healthy Males
NCT03102567Phase 1Completed
- Sponsor
- Galapagos NV
- Start
- Oct 2016
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GLPG1205 in idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by Galapagos NV. Primary endpoints: Number of subjects with adverse events, Number of subjects with abnormal laboratory evaluations and 7 more. Started Oct 2016; status: completed.
02
Drugs
GLPG1205
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT03102567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03102567.